However, a Phase I open-label trial of the allosteric mTORC1 inhibitor everolimus in combination with the PARP inhibitor niraparib in patients with advanced ovarian and breast cancer is currently recruiting (NCT03154281), as well as a Phase IV study in South Korea (NCT02688881) dispensing sirolimus as a monotherapy in patients with refractory solid tumors (PIK3CA mutation, PIK3CA amplification, PIK3CA-AKT pathway aberration). The gene discussed is PIK3CA; the disease is breast cancer.